Glucose regulatory protein (GRP58) is known to mediate mitomycin C (MMC) -induced DNA cross-linking. However, the mechanism remains elusive. We hypothesized that thioredoxin-like domains, one at NH 2 terminus and another at COOH terminus, are required for GRP58-mediated MMC reductive activation leading to DNA cross-linking. Site-directed mutagenesis mutated cysteines in thioredoxin domains to serines. Wild-type (WT) and mutant GRP58 were cloned in pcDNA to produce GRP58 V5-tagged WT and mutant proteins on transfection in mammalian cells. Human colon carcinoma (HCT116) cells transiently expressing and Chinese hamster ovary cells stably expressing WT and mutant GRP58 were analyzed for MMC-induced DNA cross-linking. WT GRP58 was highly efficient in MMC-induced DNA cross-linking. However, both NH 2 -and COOH-terminal thioredoxin mutants showed significant reduction in MMC-induced DNA cross-linking. The coexpression of GRP58 with thioredoxin reductase 1 and/or treatment of cells with NADPH increased MMC-induced DNA crosslinking from the WT GRP58. In similar experiments, siRNA inhibition of thioredoxin reductase 1 led to decreased MMC-induced DNA cross-linking. Further experiments revealed that mutations in thioredoxin domains led to significant decrease in metabolic reductive activation of MMC. These results led to conclusion that GRP58, through its two thioredoxin-like domains, functions as a reductase leading to bioreductive drug MMC activation and DNA cross-linking.
Introduction
Glucose regulatory protein 58 (GRP58), also known as ERp57, is a 58-kDa glucose regulatory protein with significant homology to protein disulfide isomerase (1, 2) . GRP58 is a member of the family of glucose-regulated proteins that are activated on glucose deprivation and have shown clinical applications to diseases associated with endoplasmic reticulum stress and cancer (3) . GRP58 has two thioredoxin-like domains and is suspected to function as thiol-dependent oxidoreductase (1, 2, 4) .
GRP58, localized in endoplasmic reticulum, specifically interacts with glycoproteins such as calnexin and calreticulin, playing an important role as a molecular chaperone during glycoprotein biosynthesis and folding (5, 6 ). GRP58 has also been shown to be involved in the assembly of newly synthesized MHC class I molecules, a process that also involves the chaperones calnexin and calreticulin (5) . The presence of GRP58 has also been shown in cytosolic and nuclear fractions (7 -9) . In the nucleus, GRP58 has been indicated as a component of the subset of nuclear matrix proteins that are responsible for DNA attachment to the nuclear matrix and for the formation of DNA loops due to GRP58 binding capacity to DNA (7, 8) . In the cytosol, GRP58 has been identified as a chaperone for the signal transducer and activator of transcription (STAT) signaling in which STAT3 proteins function in the cytoplasm as complexes with novel accessory scaffolding proteins (9) .
Bioreductive drugs play a significant role in the treatment of tumors of different organs. Bioreductive drug development is based on two major factors. The first is to develop drugs that are activated by specific reductase enzymes and the second is to identify tumor types that are rich in those reductase enzymes (10, 11) . In addition, bioreductive drug development is also based on differences in oxygen content and cellular pH between normal and tumor tissues (10, 11) . Several quinones occupy a special place in bioreductive therapy because of their tendency to undergo reductive activation by different reductases in aerobic and hypoxic conditions. These include mitomycin C (MMC), indoloquinone, 2,5-diaziridinyl-1,4-benzoquinone (DZQ), and 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954; refs. 10 -13) . MMC and its analogues are known to be effective against several tumor tissue types including colon, breast, and head and neck (14) . MMC is also interesting because this is used as a prototype drug to study mechanisms associated with bioreductive drug activation. MMC is reductively activated to 2,7-diaminomitosene, which cross-links DNA, leading to cell death. Recently, the cytosolic GRP58 protein was shown to play a significant role in MMC-induced DNA cross-linking (14) . It was reported that GRP58 is expressed higher in certain tumor tissues including breast, uterus, lung, and stomach (15) . Therefore, GRP58 is a protein that qualifies as a target for antitumor drug development. However, the mechanism of GRP58-mediated MMCinduced DNA cross-linking remains unknown.
We hypothesized that GRP58, containing two thioredoxinlike domains, functions as a reductase. The present studies show that both thioredoxin-like domains, one at NH 2 terminus and the other at COOH terminus of protein, are required for reductive activation of MMC leading to DNA cross-linking. Site-directed mutagenesis of cysteines to serines in thioredoxin-like domains had no effect on subcellular distribution of GRP58. However, thioredoxin mutations abrogated the capacity of GRP58 to catalyze reductive activation of MMC and DNA cross-linking. Overexpression and siRNA inhibition studies with thioredoxin reductase 1 (TrxR1) revealed the requirement of TrxR1 and NADPH for GRP58-mediated reductive activation of MMC and DNA cross-linking.
Materials and Methods

Materials
The Chinese hamster ovary (CHO-K1) and human colon carcinoma (HCT116) cell lines were obtained from American Type Culture Collection. MMC was purchased from SigmaAldrich Chemical Co. Deoxycytidine 5 ¶-[a-32 P]triphosphate was obtained from Perkin-Elmer Life and Analytical Sciences. Thioredoxin reductase siRNA was procured from Dharmacon. Cell culture reagents were obtained from Invitrogen. All other chemicals and reagents used in this study were of highest purity available commercially.
Cell Culture and Transfection Human colon carcinoma (HCT116) cells were grown in McCoy's 5A (modified) medium with 10% fetal bovine serum, penicillin (40 units/mL), and streptomycin (40 Ag/mL; Invitrogen) at 37jC in 95% air and 5% CO 2 incubator. The cells were grown in monolayer overnight and transfected with pcDNA-GRP58 wild-type (WT) alone or cotransfected with pcDNA-TrxR1 using Effectene transfection reagent (Qiagen). NADPH at 200 mmol/L final concentration was included in the medium in separate experiments at the time of transfection to study the role of NADPH as a cofactor for thioredoxin reductase. Similarly for silencing of TrxR1, cells grown in monolayer were transfected with TrxR1 siRNA at 10 nmol/L final concentration using Lipofectamine RNAi MAX reagent, following the protocol as recommended by the manufacturer. In case of TrxR1 overexpression, the cells were harvested 24 h posttransfection, and in case of silencing, the cells were grown for 48 h following transfection with siRNA, and then harvested and homogenized to prepare the cytosolic fractions or total cell lysates by procedures as described.
Site-Directed Mutagenesis of NH 2 -and COOH-Terminal Thioredoxin-like Domains in GRP58 and Generation of CHO Cells Stably Overexpressing WT and Mutant
GRP58 Proteins
The construction of pcDNA-GRP58 WT-V5 plasmid expressing the WT mouse GRP58 protein tagged with V5 peptide has previously been described (15) . Using GeneTailor site-directed mutagenesis system (Invitrogen), the cysteines in the NH 2 -and COOH-terminal thioredoxin-like domains of GRP58 at positions 57 and 60 and at positions 456 and 459, respectively, were mutated to serine residues. The PCR mutagenesis primers used for making mutation were, in NH 2 -terminal thioredoxin-like domain, 5 ¶-GTTC-TTCGCCCCCTGGA GTGGACATA GCAAGAGGCT-3 ¶, and in COOH-terminal thioredoxin-like domain, 5 ¶-ATTT-TACGCCCCTTGGAGTGGCCACAGTAAGAATCTGG-3 ¶; the mutated bases are shown in italics. The WT and mutant plasmid constructs, on transfection into mammalian cells, express GRP58 WT and GRP58 M1 (NH 2 -terminal mutations), GRP58 M2 (COOH-terminal mutations), and GRP58 DM (both NH 2 -and COOH-terminal mutations) mutant proteins. The CHO/DHFR À cells were grown in monolayer culture in Iscove's modified Dulbecco's medium with 4 mmol/L L-glutamine containing 1.5 g/L sodium bicarbonate and supplemented with 0.1 mmol/L hypoxanthine/ 0.016 mmol/L thymidine and 10% fetal bovine serum at 37jC under 5% CO 2 atmosphere. Overnight cultures were transfected in separate experiments with pcDNA (vector control), pcDNA-GRP58 WT-V5, pcDNA-GRP58 M1-V5, pcDNA-GRP58 M2-V5, and pcDNA-GRP58 DM-V5 plasmids (2 Ag per 100-mm dish) using Effectene transfection reagent (Qiagen). Seventy-two hours after transfection, the cells were washed with 1Â PBS without calcium and magnesium, trypsinized, and subcultured in 150-mm cell culture dish in medium containing 400 Ag/mL G418. The cells were allowed to grow for 14 days (medium changed every 2 days). The visible individual colonies were selected and expanded in 96-well plates and the clones were stabilized by subculturing subsequently in 24-, 12-, and 6-well plates and then transferred to 100-mm dish. All the stabilized clones were analyzed for the expression of WT and mutant GRP58 proteins by Western blot analysis with anti-V5 antibody. Selected clones were grown in medium deficient in G418 without the loss of GRP58 protein overexpression.
The CHO cells stably overexpressing GRP58 WT-V5 and mutant GRP58 (M1-V5, M2-V5, and DM-V5) were grown along with pcDNA vector control, and the fully confluent cells were washed with PBS, scraped in 5-mL PBS, and pelleted by centrifugation at 3,000 Â g for 10 min at 4jC. The pellet was resuspended in homogenization buffer [100 mmol/L phosphate buffer (pH 5.8), 1 mmol/L EDTA, 2 Ag/mL antipain, and 2 Ag/mL leupeptin]. The cells were manually homogenized by douncing 20 times and vortexing for 1 min. The crude cell lysate was centrifuged at 12,000 Â g for 15 min at 4jC. The supernatants were collected and further centrifuged at 105,000 Â g for 1 h and 20 min at 4jC. The supernatant cytosolic fractions were collected and used in MMC-induced DNA cross-linking assays. The mouse liver cytosol was prepared by standard procedures.
MMC-Induced DNA Cross-Linking MMC-induced DNA cross-linking assays were done by procedures as described (15) . Briefly, the two strands of the 23-bp oligonucleotides containing the MMC-binding site were selected from plasmid pBR322, synthesized, and used for the cross-linking experiments. The nucleotide sequences of the 23-bp oligonucleotide were 5 ¶-CTACATCGTGT-CATGCACAGGAT-3 ¶ (sense) and 5 ¶-AGATCCTGTGCAT-GACACGATGT-3 ¶ (antisense). The complementary strands were mixed in equal amounts and annealed by heating to 70jC for 15 min and slowly cooling to room temperature. The 3 ¶-end of the top strand was selectively labeled with deoxycytidine 5 ¶-[a-
32 P]triphosphate and DNA polymerase I large (Klenow) fragment (Promega). The labeled oligonucleotides were purified on a 15% nondenaturing polyacrylamide gel (which was eluted) and concentrated by ethanol precipitation. Reactions were incubated for 1 h at 37jC and terminated by the addition of ethanol, 10 mmol/L MgCl 2 , and 1.5 mol/L ammonium acetate. The samples were frozen at À70jC and DNA was pelleted by centrifugation at 13,700 rpm for 30 min at 4jC. The supernatant was removed and the precipitated oligonucleotides were centrifuged in SpeedVac until dry. The precipitated oligonucleotides were resuspended in DNA sequencing dye (containing formamide) and denatured by heating at 95jC for 15 min, and then rapidly cooled on ice. The samples were analyzed on a 15% denaturing polyacrylamide gel containing 8 mol/L urea and cross-linked; unmodified (free) oligonucleotides were detected by autoradiography done on Kodak Bio-max MS films using intensifying screens at À70jC for 18 h.
Insulin Turbidity Assay The insulin turbidity assay was done as previously described (1, 15) . In this assay, oxidized insulin was used as substrate in a catalyzed reduction reaction by DTT to measure thiol-dependent reductase activity of GRP58 WT, GRP58 M1, GRP58 M2, and GRP58 DM mutants by measuring the increase in turbidity at 650 nm. Each assay was done at 25jC and contained 130 mmol/L insulin and proteins in 100 mmol/L KH 2 PO 4 /KOH, 1 mmol/L DTT, 2 mmol/L EDTA, pH 7.0. BSA and thioredoxin (Sigma) were included in the experiment as negative and positive controls, respectively. The proteins were preincubated in the DTT-containing buffer for 5 min, and the assay was started by addition of insulin. The onset of aggregation was defined as the time where A 650 had reached the value of 0.025. Absorbance at 650 nm was measured every 10 min in a Beckman DU40 spectrophotometer. The absorbances shown by different samples were plotted and compared.
Spectrophotometric Analysis of MMC Metabolism
In vitro analysis of MMC metabolism in the presence of GRP58 WT and GRP58 thioredoxin mutants (M1, M2, and DM) were carried out in 10 mmol/L sodium phosphate buffer (pH 5.8). Protein sample (500 Ag) was taken and the volume of each sample was equalized with the homogenization buffer. NADH was used at 200 mmol/L final concentrations to serve as cofactor for the metabolic reaction and 500 mmol/L MMC final concentration was used for the assay. The sample tubes containing the reaction mixture were mixed gently and incubated in 37jC water bath. Absorbance at 554 nm was recorded after 0, 30, 60, 120, and 180 min to measure the amount of formation of MMC metabolites, particularly 2,7-diaminomitosene. Absorbance at 365 nm was also recorded at 30-min intervals to measure the disappearance of MMC. The fold increase in the amount of formation of MMC metabolites or the disappearance of MMC in the presence of mGRP58 WT, GRP58-GRP58 M1, GRP58 M2, and GRP58 DM mutant proteins was graphically depicted. Figure 1A shows the NH 2 -and COOH-terminal locations of thioredoxin-like (Trx) domains. The cysteines in the NH 2 -terminal thioredoxin-like domain were successfully mutated to serines to generate mutant GRP58 M1. Similarly, the cysteine-to-serine mutations in the COOH-terminal thioredoxin-like domain generated mutant GRP58 M2. The cysteines in both NH 2 -terminal and COOH-terminal thioredoxin-like domains were mutated to generate double mutant GRP58 DM. Expression plasmids encoding WT and mutant (M1, M2, and DM) GRP58 tagged with V5 peptide were transiently transfected in human colon carcinoma HCT116 cells in separate experiments. Western blot analysis and probing with anti-V5 antibody showed overexpression of WT-V5 and mutant GRP58-V5 proteins in transfected cells (Fig. 1B) . Vector control pcDNA, as expected, did not show V5 band. The expression of WT and mutant proteins was comparable in transiently transfected HCT116 cells. The HCT116 cells overexpressing WT and mutant proteins along with mouse liver cytosol (positive control) and BSA (negative control) were analyzed for MMC-induced DNA cross-linking. The results are shown in Fig. 1C . Overexpression of WT GRP58 protein led to a significant increase in MMC-induced DNA crosslinking, as compared with pcDNA vector control (P > 0.001). Interestingly, cysteine-to-serine mutation either in NH 2 -or COOH-terminal thioredoxin residue resulted in near complete loss of increase in MMC-induced DNA cross-linking, as observed with WT GRP58 protein. These results suggested that cysteines in NH 2 -and COOHterminal thioredoxin-like domains are required for MMCinduced DNA cross-linking. Interestingly, GRP58 DM showed 1.4-fold higher MMC-induced DNA cross-linking, as compared with GRP58 WT. The reasons for the increase in MMC-induced DNA cross-linking in case of GRP58 DM remain unknown. However, it is possible that double mutant GRP58 might directly or indirectly induce other as yet unknown factor(s) that enhance MMC-induced DNA cross-linking. It is also possible that double mutant GRP58 protein might bind and transport MMC inside the nucleus for interaction with DNA more efficiently than WT and single mutant proteins. The CHO cells were transfected with pcDNA-GRP58 WT-V5, pcDNA-GRP58 M1-V5, pcDNA-GRP58 M2-V5, and pcDNA-GRP58 DM-V5 in separate experiments and selected in the presence of antibiotic G418. Several CHO cell clones stably expressing either WT or mutant GRP58 proteins were successfully selected, expanded, and analyzed for the expression of respective proteins. The untransfected CHO cells and CHO cell clones expressing similar levels of WT and mutant M1, M2, and DM GRP58 were either lysed to generate total cell lysate or subcellular fractionated to generate cytosolic, nuclear, and microsomal fractions. Total cell lysate and the various subcellular fractions were separated on SDS-PAGE, Western blotted, and probed with anti-V5 antibody. The blot was stripped and reprobed with anti -lactate dehydrogenase (cytosolic marker) and anti-lamin (nuclear marker) antibodies to show purity of subcellular fractions ( Fig. 2A) . A comparison of total cell lysate lanes indicates that WT and mutant proteins are expressed at comparable levels in stably transfected CHO cells (Fig. 2A) . The endogenous and WT and mutant GRP58 proteins were detected in all the three subcellular fractions. Interestingly, the mutations in NH 2 -terminal, COOH-terminal, or both thioredoxin domains had no effect on subcellular distribution of GRP58. The subcellular distribution of mutant GRP58 proteins was more or less similar to WT protein. These results suggest that thioredoxin domains might not be required for subcellular localization of GRP58. Next, we used total cell lysate expressing WT and mutant proteins to carry out MMC-induced DNA cross-linking (Fig. 2B) . In the same experiment, BSA was used as negative control and mouse liver cytosol was used as positive control of MMC-induced DNA cross-linking. Similar to that observed in transient transfection in HCT116 cells in Fig. 1C , the CHO cells stably expressing GRP58 WT-V5 showed significantly increased MMC-induced DNA cross-linking, as compared B, Western blot analysis. Human colon carcinoma (HCT116) cells were transiently transfected with pcDNA control, mGRP58 WT-V5, mGRP58 M1-V5 (NH 2 -terminal thioredoxin domain mutated), mGRP58 M2-V5 (COOH-terminal thioredoxin domain mutated), or mGRP58 DM-V5 (both NH 2 -and COOHterminal thioredoxin domains mutated) plasmids. The cells were lysed and resolved in SDS-PAGE and immunoblotted with anti-V5-HRP antibody. The immunoblot was stripped and reprobed with h-actin antibody. C, MMC-induced DNA cross-linking. One milligram of total cell lysate from HCT116 cells transiently overexpressing vector control, WT GRP58, and mutants M1, M2, and DM-GRP58 was analyzed for MMC-induced DNA cross-linking. One milligram of BSA was used as negative control and same amount of mouse liver cytosol was used as positive control for MMC-induced DNA cross-linking. MMC-induced cross-linked DNA bands and the free probes are shown. Columns, mean relative densities of cross-linked bands compared with BSA control from three independent experiments; bars, SE.
Results
with BSA control (P > 0.001; Fig. 2B ). Interestingly, mutation of cysteines to serines in NH 2 -or COOHterminal thioredoxin-like domains led to a decrease in MMC-induced DNA cross-linking, as compared with WT GRP58. The mutations in COOH-terminal thioredoxin-like domain were more effective than those in NH 2 -terminal domain in reducing the amount of MMC-induced DNA cross-linking (Fig. 2B) The above results raised questions about the requirement of TrxR1 and NADPH in GRP58-mediated MMC-induced DNA cross-linking. HCT116 cells were transfected with pcDNA-GRP58 WT-V5 alone or cotransfected with pcDNA-TrxR1 and untreated or treated with NADPH in medium + reaction. In the same experiment, the cells were also cotransfected with pcDNA-GRP58 WT-V5 + TrxR1 siRNA and untreated or treated with NADPH in medium + reaction. The cells were analyzed for MMC-induced DNA cross-linking to determine the role of TrxR1 and NADPH in GRP58-mediated MMC-induced DNA cross-linking (Fig. 3A) . The overexpression of GRP58 WT significantly increased MMC-induced DNA cross-linking (Fig. 3A , compare lanes 2 and 6; P > 0.005). The transfection with TrxR1 alone slightly increased the MMC-induced DNA cross-linking (Fig. 3A , compare lanes 2 and 3 for endogenous GRP58 and lanes 6 and 7 for endogenous + transfected GRP58 WT). The treatment with NADPH further increased the MMC-induced cross-linking (Fig. 3A , compare lanes 3 and 5 for endogenous GRP58 and lanes 7 and 8 for endogenous + transfected GRP58 WT). The increase in MMC-induced DNA cross-linking was significantly higher in cells transfected with TrxR1 and treated with NADPH [ Fig. 3A , compare lanes 2 and 5 for endogenous GRP58 (P > 0.005) and lanes 6 and 8 for endogenous + transfected GRP58 WT (P > 0.001)]. In other words, increase in TrxR1 in the presence of NADPH increased GRP58-mediated MMC-induced DNA cross-linking. In the same experiment, siRNA-mediated inhibition of GRP58 significantly reduced GRP58-mediated MMC-induced DNA cross-linking (Fig. 3A , compare lanes 6 and 9; P > 0.005). The treatment with NADPH in the presence of TrxR1 siRNA failed to increase MMC-induced DNA cross-linking ( Fig. 2A, compare lanes 9 and 10) . In a related experiment, 10 nmol/L TrxR1 siRNA and not control siRNA catalyzed almost complete inhibition of TrxR1.
The above results indicated that GRP58 uses thioredoxinlike domains to function as a reductase, and it is possible that GRP58 metabolically reduces MMC to products that cross-link DNA. We carried out experiments first to determine the role of GRP58, its thioredoxin-like domains, and TrxR1 + NADPH in reduction of insulin. The results are shown in Fig. 4 . The CHO cells stably expressing WT and mutant GRP58 proteins were analyzed for their capacity to reduce insulin in the presence of DTT or TrxR1 + NADPH. BSA was used as negative control and thioredoxin was used as positive control. GRP58 WT in the presence of DTT showed time-dependent increase in reduction of insulin. Interestingly, mutant GRP58 M1 and GRP58 M2 both showed significant decrease in their capacity to reduce insulin. Intriguingly, double mutant GRP58 DM showed reduction of insulin similar to single mutants. Similar results were observed in the presence of TrxR1 + NADPH. However, the magnitude of reduction was greater than with DTT. In addition, the WT and mutant proteins showed high variation in their capacity to reduce insulin in the presence of NADPH + TrxR1. The mutant GRP58 proteins showed significantly weaker insulin reductase activity than WT protein. These results suggested that WT GRP58 protein uses thioredoxin domains to function as insulin reductase. This also raised the question of whether GRP58 could function as a MMC reductase.
It is known that MMC is metabolized by reductases such as NAD(P)H:quinone oxidoreductase 1 to 2,7-diaminomitosene, which has optimal absorption spectrum at 554 nm (16) . The absorption maximum for MMC is 365 nm (16) . Therefore, we analyzed the capacity of CHO cell lysates expressing endogenous alone or endogenous plus cDNA derived WT and mutant GRP58 to metabolize MMC to 2,7-diaminomitosene. We treated lysates with MMC for different time intervals and measured the production of 2,7-diaminomitosene at 554 nm and the disappearance of MMC at 365 nm. The results are shown in Fig. 5 . The results indicate that WT GRP58 efficiently catalyzed time-dependent reduction of MMC as evident from time-dependent appearance of metabolite (left) and disappearance of MMC (right). Intriguingly, the mutations in thioredoxin-like domains caused significant loss of MMC reductase activity. However, the magnitude of the loss of MMC reduction was observed more with mutants GRP58 DM and GRP58 M2 than with GRP58 M1.
Discussion
GRP58 is a highly conserved protein that belongs to the superfamily of thioredoxin cysteine glycine histidine cysteine -containing proteins (3). The presence of two thioredoxin-like domains suggested that GRP58 functions as an oxidoreductase (3, 5) . GRP58 was found to be localized in cytosol, nucleus, and endoplasmic reticulum and implicated in several functions including proper folding of proteins, DNA attachment to matrix, and chaperone for STAT3 (6, 8, 9) . It is expected that subcellular localization of GRP58 might be regulated by posttranslational modifications (15) . The results indicated that thioredoxin-like domains are not required for subcellular distribution of GRP58. However, the studies in this report show that GRP58 does function as an oxidoreductase that catalyzes reduction of insulin. Therefore, it is possible that GRP58 plays an important role in reduction of proteins for proper folding and/or unknown functions. It is also possible that thioredoxin-like domains are required for GRP58 interaction with other proteins, which remains to be determined. GRP58 is known to bind to DNA (17, 18) . Recently, it was shown that mutation in COOH-terminal thioredoxin domain interferes with GRP58 binding to DNA (18) . However, the significance of GRP58 binding to DNA remains unknown.
GRP58, in addition to functions listed above, is known to mediate MMC-induced DNA cross-linking (15) . This raised interesting questions about the mechanism by which GRP58 catalyzes MMC-induced DNA cross-linking. The present studies suggest that GRP58 uses thioredoxin-like domains to catalyze metabolic reduction of MMC to 2,7-diaminomitosene that cross-links DNA. This was evident from Figure 4 . A, insulin turbidity assay to assess the thiol-dependent reductase activity of GRP58 WT and GRP58 thioredoxin mutants (M1, M2, and DM). CHO cells stably overexpressing mGRP58 WT and GRP58 thioredoxin mutants (M1, M2, and DM), along with pcDNA control, were grown in monolayer to full confluency. Cells were harvested and cytosols made by standard protocol. Thiol-dependent reductase activities of thioredoxin protein (positive control), BSA (negative control), and GRP58 WT, GRP58 M1, GRP58 M2, and GRP58 DM, each at 250 Ag protein concentration, were measured by their ability to reduce insulin in vitro to cause turbidity at 650 nm. Points, mean of three independent assays; bars, SE.
B, effect of TrxR1 and h-NADPH on the reductase activity of GRP58 WT and GRP58 thioredoxin-mutant proteins. TrxR1 protein (Sigma; 5 Ag/mL) and h-NADPH (200 mmol/L) were added to the insulin turbidity assay mixture and incubated for 30 min at 37jC before the addition of insulin to initiate the reaction. Absorbance at 650 nm was measured at 10-min intervals and the graph plotted as a function of time. Points, mean obtained of three independent assays; bars, SE.
the observations that mutant GRP58 bearing cysteine-toserine mutations in NH 2 -or COOH-terminal thioredoxinlike domains resulted in the loss of metabolic reduction of MMC and DNA cross-linking. The data also suggested that both thioredoxin-like domains of GRP58 are required for efficient catalysis of MMC reduction and DNA cross-linking. However, it seemed that COOH-terminal thioredoxin-like domain might be more effective than NH 2 -terminal domain in catalyzing metabolic reduction of MMC leading to DNA cross-linking. This might or might not be related to structure/folding of protein. We did not observe a difference in capacity for M1 and M2 mutant to catalyze MMC-induced DNA cross-linking in transient transfection in Fig. 1B . Transient transfections overexpressed much higher levels of protein than stable transfected cells. It is possible that the difference between M1 and M2 was suppressed in transient transfection. However, the consensus is that both cells lines and two different transfection methods showed reduced capacity of M1 and M2 mutant GRP58 to catalyze MMC-induced DNA crosslinking, as compared with WT protein. It was clearly evident that TrxR1 + NADPH are required presumably to reduce cysteines in thioredoxin-like domains of GRP58 for reduction of MMC leading to DNA cross-linking.
MMC cross-linking analysis revealed an unexpected result with double mutant. Both transient transfection of double mutant GRP58 in HCT116 and stable transfection in CHO cells revealed increase in MMC-induced DNA crosslinking that was higher than WT GRP58 protein. Further experiments revealed that thioredoxin double mutant GRP58 protein was less efficient in metabolic reduction of MMC in transfected HCT116 cells, as compared with WT protein. In other words, double mutant GRP58 protein showed reduced metabolic activation of MMC but increased DNA cross-linking. The reasons for increased DNA cross-linking with double mutant GRP58 protein remain unknown. However, it is possible that double mutant GRP58 might directly or indirectly induce other as yet unknown factor(s) that enhance MMC-induced crosslinking of DNA. It is also possible that double mutant GRP58 protein might bind and transport MMC inside the nucleus for interaction with DNA more efficiently than WT and single mutant proteins.
It is expected that GRP58 catalyzes metabolic reduction of not only MMC but also other antitumor drugs, including indoloquinone, leading to DNA cross-linking and/or cell death. Interestingly, higher expression of GRP58 was reported in human breast, lung, uterus, and stomach tumors (15) . In addition, GRP58 is significantly activated in cells deprived of glucose (1) . It is also known that the core of tumor tissues is not only hypoxic but also deprived of glucose (19) . These observations combined with the present studies suggest that GRP58 could be a potential target for future investigations on drug development. The overexpressed and glucose deprivation -activated GRP58 might activate antitumor drug selectively in killing of A, generation of MMC metabolites, particularly 2,7-diaminomitosene, was measured spectrophotometrically at 554 nm during in vitro metabolism of MMC by GRP58 WT and mutant proteins. B, disappearance of MMC measured at 365 nm during in vitro metabolism of MMC by GRP58 WT and mutant proteins. Points, mean absorption values from three independent assays; bars, SE.
tumor cells that generally escape radiation treatment and are points of recurrence of tumor growth.
In conclusion, we have investigated the mechanism of the role of GRP58, a potential target in drug development, in MMC-induced DNA cross-linking. The two thioredoxinlike domains in GRP58, after getting reduced by thioredoxin reductase-1 and NADPH, metabolically reduce MMC to 2,7-diaminomitosene, which in turn cross-links DNA.
